Nairobi, Kenya — A recent study has highlighted that enhancing the distribution and provision of rabies vaccines in Tanzania and Kenya could dramatically cut the number of preventable fatalities from this lethal disease. The research, published in the Journal Vaccine, was a collaborative effort among institutions including the University of Glasgow, Ifakara Health Institute, and the University of Nairobi, backed by the Wellcome Trust.
The findings advocate for the World Health Organization’s recommendation to utilize the intradermal (ID) vaccination method, allowing health workers to treat multiple patients with a single vial. This technique promises to reduce overall vaccine consumption by over 55%, while also mitigating the risk of shortages that often plague rural clinics.
Rabies claims about 59,000 lives globally every year, primarily in low- and middle-income nations, even when effective post-exposure prophylaxis (PEP) is available. Many people succumb to the disease due to delayed access to these critical vaccines, often caused by logistical hurdles such as frequent stockouts, the high cost of treatment, and long travel distances to health facilities.
This study analyzes existing rabies vaccine supply chains and assesses management strategies using actual data from Kenya and Tanzania. By identifying ways to strengthen the distribution framework for these vaccines, the researchers aim to ensure timely intervention for individuals exposed to the rabies virus.
Key among the recommendations is the adoption of intradermal vaccination in settings that experience multiple cases daily. Improved stocking methods and decentralizing vaccination services to local clinics can significantly enhance the ability to provide PEP more effectively, according to the researchers.
“It is unacceptable that people are still dying from rabies when effective vaccines are available,” said Martha Luka, the study’s lead author and a postgraduate researcher at the University of Glasgow. She emphasized the potential of efficient stock management coupled with dose-sparing vaccination methods to protect more individuals while using fewer resources.
In Tanzania, where PEP is generally limited to central hospitals, increasing accessibility to nearby clinics could level the playing field for people in remote locations. The study suggests that restocking strategies should align with patient volumes in various clinics, using tailored guidelines for determining stock levels and reorder timings to respond rapidly to changes in demand.
Kennedy Lushasi, co-author of the study and a researcher at the Ifakara Health Institute, noted the practical implications of their findings. “By integrating vaccines into existing supply frameworks and broadening access to local clinics, we can save lives and reduce costs,” he said, urging policymakers to act swiftly to leverage these recommendations.
With Gavi, the Vaccine Alliance initiating funding for expanded access to rabies vaccines, the timing of this research is particularly critical. Gavi aims to eliminate human deaths from dog-mediated rabies by 2030 by integrating vaccine distribution into national supply chains across Africa and Asia while simultaneously promoting canine vaccination.
Mumbua Mutunga, also a co-author, highlighted the transformative potential of Gavi’s investment in public health initiatives. “Our research illustrates that employing effective supply chain strategies, alongside the introduction of intradermal injections, can fortify nations’ defenses against rabies, particularly for vulnerable populations,” she said.
With these strategies in place, achieving ambitious goals for rabies prevention is within reach. Luka concluded by asserting that countries must mobilize effectively to capitalize on Gavi’s investment and build robust healthcare systems that guarantee timely access to PEP for those at risk.